Clinical efficacy and safety of carelizumab combined with radiofrequency ablation in the treatment of cirrhotic hepa-tocellular carcinoma patients
Di Liang
Ablipiz Ablikimu
Guo Qingliang
Zhao Xiaofei
Ding Jing
Abstract：Objective To observe the clinical efficacy and safety of carrelizumab combined with radiofrequency ablation in the treatment of patients with liver cirrhosis and liver cancer.Methods Ninety patients with primary liver cancer combined with liver cirrhosis were admitted to the General Surgery Center of Beijing You'an Hospital affiliated with Capital Medical University from January 2022 to February 2023,and were divided into the observation group(n=45)and the con-trol group(n=45)by the method of randomized numerical table.Both groups were treated with radiofrequency ablation for hepatocellular carcinoma,and the patients in the observation group were treated with pre-operative and post-operative com-bined application of karelizumab on this basis.After 2 months of treatment,the clinical efficacy of the two groups was com-pared;liver function indexes(serum total bilirubin(TB),alanine aminotransferase(ALT)and aspartate aminotransferase(AST)),tumor markers(alpha-fetoprotein(AFP),glycoprotein antigen 199(CA199)and hepatocellular carcinoma high-ex-pression gene 10(PEG10))and immunity indexes(CD4,CD4 and CD4)were detected in the patients of both groups.We cal-culated the incidence rate of adverse events during the treatment period,including changes in the levels of CD4+ T cells,CD8+Tcells and CD4+/CD8+ ratio.Results Totaleffective rate of the observation group and the controlgroup was not statistically significant(91.11%vs.84.44%,χ2=0.932,P=0.334);Serum TB,ALT and AST levels of patients in the obser-vation group were lower than those in the control group after treatment(t/P=1.993/0.049,3.505/0.001,2.520/0.014),and serum AFP,CA199 and PEG10 levels were lower than those in the control group(t/P=2.410/0.018,3.076/0.003,3.552/0.001),and the peripheral blood CD4+T cell ratio,CD8+ T cell ratio and CD4+/CD8+ ratios were higher than those in the control group(t/P=5.621/<0.001,3.438/0.001,3.281/0.001);the incidence rate of total adverse events during the treatment period was high-er in the observation group compared with the control group.control group was not statistically significant(17.78%vs.13.33%,χ2=0.338,P=0.561).Conclusion Carelizumab combined with radiofrequency ablation can improve the clinical effi-cacy of hepatocellular carcinoma patients with combined cirrhosis to a certain extent,which may be related to the reduction of patients'tumor marker levels and improvement of immune function,and this combination treatment plan has certain clini-cal application prospects.
Keywords：Hepatocellular carcinomaCirrhosisKarelizumabRadiofrequency ablation
Publication Date：2024-03-18
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 318-322 )